NEW YORK (GenomeWeb) – Two years after acquiring Swedish startup Vanadis Diagnostics, PerkinElmer is preparing to launch the company's noninvasive prenatal testing technology as a low-cost and user-friendly alternative to existing NIPTs for fetal aneuploidy screening, with the goal of expanding access to cell-free DNA prenatal screening.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.